AI-Driven Tool for Melanoma Diagnosis Displays Promising Results
Source: Targeted Oncology, February 2023
A positive diagnostic performance was seen with the Dermaslayer device which is used as a decision support system for assessing potential melanoma. Findings included 95% sensitivity and 86% specificity in the first prospective study of its kind conducted in primary care settings, according to AI Medical Technology (NCT05172232).
“Indeed, [these are] exciting results, these numbers show potential of not only improving future visual diagnostic accuracy, but also decreasing the amount of workload that dermatologists too often are dealing with in their daily practice. Nevertheless, additional studies are necessary to confirm the positive results. Human-computer collaboration is here to stay and I’m looking forward to its implementation in the field of skin cancer and dermatology in general,” added Olle Larkö, professor in Dermatology & Venereology and former Dean at Sahlgrenska University, in the press release.
The clinical trial took place across 37 Swedish primary care facilities and evaluated a diagnostic decision support system empowered with advanced artificial intelligence called Dermalyser. Findings showed that Dermalyser outperformed primary care physicians and dermatologists.